Drug Search Results
More Filters [+]

Olumacostat glasaretil

Alternative Names: olumacostat glasaretil
Latest Update: 2019-06-19
Latest Update Note: News Article

Product Description

Mechanisms of Action: Sebum Production Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Olumacostat glasaretil

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Acne Vulgaris

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

DRM01B-ACN05

P3

Completed

Acne Vulgaris

2018-04-27

DRM01B-ACN04

P3

Completed

Acne Vulgaris

2017-12-21

DRM01B-ACN03

P3

Completed

Acne Vulgaris

2017-11-28

Recent News Events